ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor (Q81249003)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18469855 AND SRC:MED&resulttype=core&format=json

7 January 2020

title

ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18469855 AND SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18469855 AND SRC:MED&resulttype=core&format=json

7 January 2020

author name string

C Osipo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18469855 AND SRC:MED&resulttype=core&format=json

7 January 2020

P Patel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18469855 AND SRC:MED&resulttype=core&format=json

7 January 2020

P Rizzo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18469855 AND SRC:MED&resulttype=core&format=json

7 January 2020

A G Clementz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18469855 AND SRC:MED&resulttype=core&format=json

7 January 2020

L Hao

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18469855 AND SRC:MED&resulttype=core&format=json

7 January 2020

T E Golde

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18469855 AND SRC:MED&resulttype=core&format=json

7 January 2020

publication date

12 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18469855 AND SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18469855 AND SRC:MED&resulttype=core&format=json

7 January 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18469855 AND SRC:MED&resulttype=core&format=json

7 January 2020

issue

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18469855 AND SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

5019-5032

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18469855 AND SRC:MED&resulttype=core&format=json

Issues and controversies in the treatment of HER2 positive metastatic breast cancer

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Notch signaling: cell fate control and signal integration in development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Control of cell proliferation in the Drosophila eye by Notch signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Mechanism of action of trastuzumab and scientific update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Intracellular Cleavage of Notch Leads to a Heterodimeric Receptor on the Plasma Membrane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Reciprocal regulation of Notch and PI3K/Akt signalling in T-ALL cells In Vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Humanization of an anti-p185HER2 antibody for human cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

High-level JAG1 mRNA and protein predict poor outcome in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Involvement of Notch1 in the development of mouse mammary tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Notch, Myc and breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2( ) metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Jagged: A mammalian ligand that activates notch1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

The Notch1 receptor is cleaved constitutively by a furin-like convertase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Notch signaling in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Arbiter of differentiation and death: Notch signaling meets apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Herceptin: mechanisms of action and resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Paradoxical Action of Fulvestrant in Estradiol-Induced Regression of Tamoxifen-Stimulated Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

The response of CD24(-/low)/CD44 breast cancer-initiating cells to radiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Notch in mammary gland development and breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Activated Notch1 signaling cooperates with papillomavirus oncogenes in transformation and generates resistance to apoptosis on matrix withdrawal through PKB/Akt

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Requirement for cyclin D3 in lymphocyte development and T cell leukemias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Aberrant activation of notch signaling in human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Ectodomain shedding and intramembrane cleavage of mammalian Notch proteins is not regulated through oligomerization.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Phospholipid membrane composition affects EGF receptor and Notch signaling through effects on endocytosis during Drosophila development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

The Ins and Outs of Notch Signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149

Biology of HER2 and its importance in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/ONC.2008.149